Trial Profile
Evaluation of Technetium Tc 99m Tilmanocept Localization, Retention, and Distribution in Primary Cutaneous Kaposi's Sarcoma (KS) and Lymphatic Drainage From KS Lesions by SPECT/CT Imaging
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Tc 99m tilmanocept (Primary)
- Indications Kaposi's sarcoma
- Focus Diagnostic use
- Sponsors Navidea Biopharmaceuticals
- 04 Jun 2015 According to Navidea Biopharmaceuticals media release, the data from this trial will be presented at 18th international workshop on Kaposis Sarcoma HerpesVirus (KSHV) and Related Agents in Hollywood, Florida.
- 03 May 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 22 Apr 2015 Complete results will be presented in the coming months, as per Navidea Biopharmaceuticals media release.